Dr. Thomas Powles explains standard treatment for metastatic urothelial cancer

"This is the first data to show that antegrade instillation of UGN-101 had lower ureteral stricture rates compared [with] retrograde approaches,” said Josh Gottlieb, DO.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

The investigators found that patients who experienced recurrence following BCG therapy were more likely to have BRS3 tumors compared with BRS1 or BRS2.

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

The 5-year metastasis-free survival rate was 75% with trimodality therapy vs 74% with radical cystectomy.

Increasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.